Long-term Study of Semapimod (CNI-1493) for Treatment of Crohn's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

119

Participants

Timeline

Start Date

December 31, 2002

Primary Completion Date

July 31, 2004

Study Completion Date

September 30, 2004

Conditions
Crohn's Disease
Interventions
DRUG

Semapimod

60 mg IV x 3 days q 6 - 8 weeks

Trial Locations (26)

10128

Asher Kornbluth, MD, New York

11021

Long Island Clinical Research Associates, Great Neck

14621

Rochester General Hospital, Rochester

30024

Advanced Gastroenterology Associates, Suwanee

30342

Atlanta Gastroenterology Associates, Atlanta

37620

Gastroenterology Associates, Bristol

60611

Northwestern University, Chicago

94115

University of California, San Francisco, San Francisco

Unknown

Cliniques Universitaires Saint-Luc, Brussels

Academic Hospital Gasthuisberg, Leuven

Benjamin Franklin University, Berlin

Medizinischen Hochschule-Hannover, Hanover

Universitats Klinikum Heidelberg, Heidelberg

University of Kiel, Kiel

Gastroenterologische Fachpraxis, Minden

Stadtisches Krankenhaus Munchen-Bogenhausen, München

University of Munster, Münster

Rambam Medical Center, Haifa

Hadassah Medical Center, Jerusalem

Shaare Zedek Hospital, Jerusalem

Tel Aviv Sourasky Medical Center, Tel Aviv

Chaim Sheba Medical Center, Tel Litwinsky

Academic Medical Center, Amsterdam

Free University (Vrije Universiteit), Amsterdam

Academisch Ziekenhuis Maastricht, Maastricht

Erasmus Medical Center, Rotterdam

Sponsors
All Listed Sponsors
lead

Ferring Pharmaceuticals

INDUSTRY